Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
D000577:Amides / Q000494:pharmacology; D000818:Animals; D000941:Antigens; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001391:Azo Compounds / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000494:pharmacology; D005260:Female; D006087:Graft vs Host Reaction; D006648:Histocompatibility; D007093:Imidazoles / Q000494:pharmacology*; D007125:Immunogenetics; D007939:Leukemia L1210 / Q000276:immunology* / Q000401:mortality; D009052:Leukemia Virus, Murine / Q000187:drug effects; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009154:Mutation; D009368:Neoplasm Transplantation; D014226:Triazenes / Q000494:pharmacology
D000577:Amides; D000941:Antigens; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D001391:Azo Compounds; D007093:Imidazoles; D014226:Triazenes; D003520:Cyclophosphamide